In 1987, a young researcher decided to seize the opportunity to build on the promise of molecular biology that had helped to create a critical mass of companies in the biotech arena. At that time, research into central nervous system disorders was in its infancy and Cephalon Founder, scientist and CEO, Frank Baldino, Jr. Ph.D. envisioned creating a different kind of company that would be a hybrid of the best assets, and hopefully none of the worst features, of pharmaceutical, biotech, and specialty pharmaceutical companies. Today, Cephalon is the only top biotech with a founding CEO still at the helm.
Cephalon has demonstrated success in acquiring and marketing innovative, first in class or best in class, high-growth products, while leveraging its critical investments in scientific discovery. Today, Cephalon markets eight proprietary products in the United States, more than 20 products outside of the United States. Add to that outstanding financial growth, membership on the Fortune 1000 list, the NASDAQ 100 and in the Community of Global Growth Companies of the World Economic Forum and the rewards of two decades of hard work and dedication shows.
Looking ahead, Frank Baldino hopes to continue to expand the company’s global presence and create effective products, while staying true to his original dreams and inspirations. “When a product is successful it is very satisfying to see how it changes people's lives for the better,” he says. “This is why we keep working so hard.”